Cisplatin Pharmacokinetics and Its Nephrotoxicity in Diabetic Rabbits

Background: This study was designed to investigate the relationship between the attenuation of cisplatin (CDDP)-induced nephrotoxicity in experimental diabetic rabbits and the plasma pharmacokinetics of the free ultrafilterable and total plasma platinum (Pt) levels. Methods: Two groups of age-matched male New Zealand white rabbits were used; the first group consisted of rabbits with streptozotocin-induced diabetes (single i.v. bolus dose of streptozotocin of 65 mg/kg in citrate buffer, pH 4.6), and the second group of nondiabetic rabbits treated with the same volume of citrate buffer. Both groups were treated with CDDP (5 mg/kg, single i.v. bolus dose) 3 days after induction of the diabetic state in the first group. The plasma Pt levels were followed for 4 h after CDDP administration, in which the free ultrafilterable and total plasma Pt concentrations were determined by atomic absorption spectrometry. The pharmacokinetic parameters of free ultrafilterable plasma Pt were determined using a noncompartment pharmacokinetic model of analysis. Results: The total plasma Pt levels declined in a biphasic manner and were adequately described by a two-compartment model. No significant change was observed in the pharmacokinetics of either the free ultrafilterable or total plasma Pt levels in the diabetic group in comparison with the control nondiabetic group (p > 0.05). However, 4 h after CDDP administration, the total plasma Pt level of the nondiabetic group was significantly higher than that of the diabetic rabbits (p < 0.001). Indices of nephrotoxicity were determined 7 days after CDDP administration. The results revealed that the diabetic state protected against CDDP-induced nephrotoxicity. The nondiabetic rabbits exhibited highly significant elevations in the serum creatinine and urea levels and a decrease in the serum albumin level (p < 0.001) in comparison with the diabetic group. Conclusions: These findings might suggest that the reduction in CDDP-induced nephrotoxicity in diabetic rabbits is not due to a change in the plasma pharmacokinetic profile within the drug follow-up period. It could be anticipated that the rapid decline in the total plasma Pt level after CDDP administration to diabetic rabbits, as well as the reduction in the terminal elimination half-life of the total plasma Pt level might be responsible for the reduction in CDDP-induced nephrotoxicity. Also, alterations in the how kidneys of diabetics deal with the renal excretion of Pt and reduction of its accumulation in kidney tissue are not excluded.

[1]  T. Larson,et al.  Role of nitric oxide in intrarenal hemodynamics in experimental diabetes mellitus in rats. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[2]  M. Lee,et al.  Pharmacokinetics of a New Proton‐pump Inhibitor, YJA‐20379‐8, after Intravenous and Oral Administration to Rats with Streptozotocin‐induced Diabetes Mellitus , 1999, The Journal of pharmacy and pharmacology.

[3]  J. M. Park,et al.  Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. , 1996, Research communications in molecular pathology and pharmacology.

[4]  H. Pehamberger,et al.  Effects of cisplatin on urinary thromboxane B2 excretion , 1995, Clinical pharmacology and therapeutics.

[5]  B. Richelsen,et al.  Inhibition of renal ornithine decarboxylase activity fails to reduce kidney size and urinary albumin excretion in diabetic rats with manifest kidney hypertrophy , 1995, Molecular and Cellular Endocrinology.

[6]  K. Patel,et al.  Reduced renal sympathoinhibition in response to acute volume expansion in diabetic rats. , 1994, The American journal of physiology.

[7]  M. Jones,et al.  Association between increased atrial natriuretic peptide and reduced cisplatin nephrotoxicity in rats. , 1992, The Journal of pharmacology and experimental therapeutics.

[8]  O. Medvedev,et al.  [The indices of systemic and regional hemodynamics in waking rats with streptozotocin diabetes]. , 1992, Fiziologicheskii zhurnal.

[9]  S. Takahiro,et al.  Change of lipid peroxide levels in rat tissues after cisplatin administration. , 1991 .

[10]  Y. Singh,et al.  Renal Metallothionein and Platinum Levels in Diabetic and Nondiabetic Rats Injected with Cisplatin , 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[11]  L. A. Scott,et al.  Renal accumulation and urinary excretion of cisplatin in diabetic rats. , 1991, Toxicology.

[12]  K. Murata,et al.  Effects of insulin on plasma renin activity, plasma atrial natriuretic peptide and body fluid volume in diabetes mellitus. , 1990, Japanese heart journal.

[13]  L. A. Scott,et al.  Influence of streptozotocin (STZ)-induced diabetes, dextrose diuresis and acetone on cisplatin nephrotoxicity in Fischer 344 (F344) rats. , 1990, Toxicology.

[14]  K. Patel,et al.  Reduced renal responses to volume expansion in streptozotocin-induced diabetic rats. , 1989, The American journal of physiology.

[15]  L. A. Scott,et al.  Attenuation of cisplatin nephrotoxicity by streptozotocin-induced diabetes. , 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[16]  B. Kasiske,et al.  Glomerular hemodynamic and structural alterations in experimental diabetes mellitus , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  B. Brenner,et al.  Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. , 1987, The Journal of clinical investigation.

[18]  M. Gemba,et al.  Stimulatory effect of cisplatin on production of lipid peroxidation in renal tissues. , 1987, Japanese journal of pharmacology.

[19]  H. Kamiya,et al.  [Studies on adequate intervals of cisplatin administration to ameliorate cisplatin-induced nephrotoxicity]. , 1986, Gan to kagaku ryoho. Cancer & chemotherapy.

[20]  K. Jabboury,et al.  Cis‐diamminedichloroplatinum (II) by 5‐day continuous infusion a new dose schedule with minimal toxicity , 1984, Cancer.

[21]  T. F. Patton,et al.  Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man. , 1978, Cancer treatment reports.

[22]  W. Whitmore,et al.  Improvement of Cis‐dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model , 1977, Cancer.

[23]  N. Hill,et al.  Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. , 1975, Cancer chemotherapy reports.

[24]  A. Newman,et al.  Coordination complexes of platinum as antitumor agents. , 1975, Cancer chemotherapy reports.

[25]  P. Conran.  Pharmacokinetics of Platinum Compounds , 1974 .

[26]  D. Taylor,et al.  Metabolism of platinum ( 14 C)ethylenediamine dichloride in the rat. , 1973, Biochemical pharmacology.

[27]  R. P. Spencer,et al.  Synthesis and distribution of a radiolabeled antitumor agent: cis-diamminedichloroplatinum. II. , 1972, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  J. Cook,et al.  Reduced nicotinamide adenine dinucleotide-coupled reaction for emergency blood urea estimation. , 1971, Clinica chimica acta; international journal of clinical chemistry.

[29]  T. Feichtmeir,et al.  The quantitation of albumin based on its dyebinding capacity. , 1956, American journal of clinical pathology.

[30]  H. Taussky,et al.  ON THE COLORIMETRIC DETERMINATION OF CREATININE BY THE JAFFE REACTION , 1945 .